Inovio Q1 net loss $79.1M ($0.36/share); CEO Kim resigns, Shea appointed; discontinues INNOVATE trial

INOVIO PHARMACEUTICALS, INC.

Net loss $79.1M ($0.36/share) vs $54.4M ($0.27) in Q1 2021; revenue $199K.
CEO J. Joseph Kim resigns; Jacqueline Shea (former COO) appointed President and CEO; Shea base salary $700K.
Phase 3 INNOVATE trial for COVID-19 vaccine discontinues; prioritize heterologous booster strategy.
VGX-3100 BLA for cervical HSIL not expected in 2023; REVEAL2 amended to biomarker-selected population.
Cash and investments $360.4M at Mar 31, 2022, down from $401.3M at Dec 31, 2021.

item 2.02 item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Jacqueline E. Shea

President and Chief Executive Officer

INO · INOVIO PHARMACEUTICALS, INC.

Effective: 2022-05-10
Filed: May 10, 2022, 7:59 PM ET

the Board appointed Dr. Jacqueline Shea, currently the Company’s Chief Operating Officer, to serve as the Company’s President and Chief Executive Officer

Departed

J. Joseph Kim

President, Chief Executive Officer and Director

INO · INOVIO PHARMACEUTICALS, INC.

Effective: 2022-05-10
Successor: Jacqueline E. Shea
Filed: May 10, 2022, 7:59 PM ET

J. Joseph Kim, President and Chief Executive Officer of the Company, resigned from those positions and also resigned as a member of the Company’s Board of Directors

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Jacqueline E. Shea was appointed as President and Chief Executive Officer at INOVIO PHARMACEUTICALS, INC..

Action: appointed
Role: President and Chief Executive Officer

Exact text from the filing

the Board appointed Dr. Jacqueline Shea, currently the Company’s Chief Operating Officer, to serve as the Company’s President and Chief Executive Officer

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

J. Joseph Kim resigned as President, Chief Executive Officer and Director at INOVIO PHARMACEUTICALS, INC..

Action: resigned
Role: President, Chief Executive Officer and Director

Exact text from the filing

J. Joseph Kim, President and Chief Executive Officer of the Company, resigned from those positions and also resigned as a member of the Company’s Board of Directors

View on SEC.gov

INOVIO PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001193125-22-146350

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.